Source: International Congress 2016 – Asthma management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Mark Lomax (Cambridge, United Kingdom), David Bell, Lucielle Mansfield, Mark Lomax. Fluticasone propionate/formoterol breath-triggered inhaler: Ease-of-use and patient preference. Eur Respir J 2016; 48: Suppl. 60, 4109

Member's Comments

No comment yet.

Related content which might interest you: Device handling study of a novel fluticasone propionate/formoterol breath-triggered inhaler Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Plume characteristics of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Plume temperature and force of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Ease of use of a two-strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Patient inhaler satisfaction with Spiromax Budesonide/Formoterol versus Diskus Fluticasone/Salmeterol in COPD Source: International Congress 2019 – Inhalers: adherence and preference Year: 2019 Late Breaking Abstract - A connected inhaler system improves adherence to fluticasone furoate/vilanterol in asthma Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Equivalence of an innovative multidose salmeterol/fluticasone dry powder inhaler vs comparator in paediatric asthma Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013 Lung deposition of fluticasone propionate/formoterol administered via a breath-triggered inhaler Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017 Add-on effects of long-acting beta2-agonists salmeterol inhaler vs tulobuterol patch in adult patients with mild-to-moderate asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Asthma management: important issues Source: Eur Respir Rev 2005; 14: 147-151 Year: 2005 Impact of age on extra-fine particle hydrofluoroalkane beclometasone dipropionate versus fluticasone propionate outcomes in asthmatic children Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Patient satisfaction with fluticasone propionate/salmeterol (FSC) HFA with an integrated dose counter Source: Eur Respir J 2005; 26: Suppl. 49, 127s Year: 2005 Comparison of HFA salmeterol-fluticasone (SFC) combination when given through breath actuated inhaler (BAI) and pressurised meter dose inhaler (pMDI) in patients with moderate-to-severe asthma Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Comparative effectiveness analysis: Extra-fine particle hydrofluoroalkane beclomethasone dipropionate vs fluticasone propionate with spacer in children Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Formoterol Aerolizer inhaler technique in patients with Asthma and COPD Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017 CHF5993 pMDI (extrafine Beclometasone Dipropionate:BDP, Formoterol Fumarate:FF, Glycopyrronium Bromide:GB) reduces Clinically Important Deteriorations (CID) in COPD: post-hoc analysis of TRILOGY study. Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017 Effect of switching from salmeterol/fluticasone dry powder inhaler to formoterol/fluticasone pressurized metered-dose inhaler in elderly asthma patients Source: International Congress 2016 – Asthma management Year: 2016 Comparable effectiveness of budesonide/formoterol combination and fluticasone for the treatment of cough variant asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Efficacy of salmeterol/fluticasone propionate combination administered via Diskus inhaler in children with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 429s Year: 2002 Fluticasone propionate/formoterol fumarate improves asthma control and reduces exacerbations compared with fluticasone Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013